Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis

References

• National Institute for Health and Clinical ExcellenceParkinson’s disease: diagnosis and management in primary and secondary care2006 Available from: http://www.nice.org.uk/CG035Accessed March 19, 2011
   Google Scholar
• Parkinson’s Disease FoundationStatistics on Parkinson’s Available from: http://www.pdf.org/en/parkinson_statisticsAccessed July 26, 2013
   Google Scholar
• SweetRDMcDowellFHFive years’ treatment of Parkinson’s disease with levodopa. Therapeutic results and survival of 100 patientsAnn Intern Med19758344564631166978
   PubMed Web of Science ®Google Scholar
• LesserRPFahnSSniderSRCoteLJIsgreenWPBarrettREAnalysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapyNeurology1979299 Pt 112531260573405
   PubMed Web of Science ®Google Scholar
• Royal Pharmaceutical Society of Great Britain, British Medical AssociationBritish National FormularyLondonBMJ Group2009
   Google Scholar
• BrooksDJDopamine agonists: their role in the treatment of Parkinson’s diseaseJ Neurol Neurosurg Psychiatr200068668568910811688
   PubMed Web of Science ®Google Scholar
• SteigerMJostWGrandasFVan CampGRisk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic reviewJ Neural Transm2009116217919119142570
   PubMed Web of Science ®Google Scholar
• KulisevskyJPagonabarragaJTolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trialsDrug Saf201033214716120082541
   PubMed Web of Science ®Google Scholar
• LeentjensAFThe role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease: a systematic reviewDrugs201171327328621319866
   PubMed Web of Science ®Google Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• DiasSWeltonNSuttonAAdesANICE technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials2011 Available from: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdfAccessed March 19, 2011
   Google Scholar
• MillsEJIoannidisJPThorlundKSchunemannHJPuhanMAGuyattGHHow to use an article reporting a multiple treatment comparison meta-analysisJAMA2012308121246125323011714
   PubMed Web of Science ®Google Scholar
• LunnDSpiegelhalterDThomasABestNThe BUGS project: evolution, critique and future directionsStat Med200928253049306719630097
   PubMed Web of Science ®Google Scholar
• GiladiNBoroojerdiBKorczynADBurnDJClarkeCESchapiraAHRotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropiniroleMov Disord200722162398240417935234
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med2000342201484149110816186
   PubMed Web of Science ®Google Scholar
• SingerCLambJEllisALaytonGA comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson’s diseaseMov Disord200722447648217318839
   PubMed Web of Science ®Google Scholar
• WattsRLLyonsKEPahwaROnset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s diseaseMov Disord201025785886620461803
   PubMed Web of Science ®Google Scholar
• MizunoYKondoTHasegawaKTransdermal rotigotine in early stage Parkinson’s disease: a randomized, double-blind, placebo-controlled trialMov Disord201328101447145023801585
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupPramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study GroupJAMA2000284151931193811035889
   PubMed Web of Science ®Google Scholar
• ShannonKMBennettJPJrFriedmanJHEfficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study GroupNeurology19974937247289305331
   PubMed Web of Science ®Google Scholar
• KulisevskyJLópez-VillegasDGarcía-SánchezCBarbanojMGironellAPascual-SedanoBA six-month study of pergolide and levodopa in de novo Parkinson’s disease patientsClin Neuropharmacol19982163583629844794
   PubMed Web of Science ®Google Scholar
• BaronePBraviDBermejo-ParejaFPergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study GroupNeurology199953357357910449123
   PubMed Web of Science ®Google Scholar
• BaronePPoeweWAlbrechtSPramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trialLancet Neurol20109657358020452823
   PubMed Web of Science ®Google Scholar
• WongKSLuCSShanDEYangCCTsoiTHMokVEfficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s diseaseJ Neurol Sci20032161818714607306
   PubMed Web of Science ®Google Scholar
• KieburtzKTwice-daily, low-dose pramipexole in early Parkinson’s disease: a randomized, placebo-controlled trialMov Disord2011261374420925067
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled trial of rotigotine monotherapy in early Parkinson’s diseaseArch Neurol200360121721172814676046
   PubMedGoogle Scholar
• ThomasABonanniLDi IorioAEnd-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson’s diseaseJ Neurol2006253121633163917219034
   PubMed Web of Science ®Google Scholar
• PoeweWRascolOBaronePExtended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trialNeurology201177875976621832218
   PubMed Web of Science ®Google Scholar
• SampaioCBronzovaJHauserRAPardoprunox in early Parkinson’s disease: results from 2 large, randomized double-blind trialsMov Disord20112681464147621542016
   PubMed Web of Science ®Google Scholar
• JankovicJWattsRLMartinWBoroojerdiBTransdermal rotigotine: double-blind, placebo-controlled trial in Parkinson diseaseArch Neurol200764567668217502466
   PubMed Web of Science ®Google Scholar
• HauserRASchapiraAHRascolORandomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s diseaseMov Disord201025152542254920669317
   PubMed Web of Science ®Google Scholar
• BrooksDJAbbottRJLeesAJA placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s diseaseClin Neuropharmacol19982121011079579296
   PubMed Web of Science ®Google Scholar
• WhoneALWattsRLStoesslAJSlower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET studyAnn Neurol20035419310112838524
   PubMed Web of Science ®Google Scholar
• OertelWHWoltersESampaioCPergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET studyMov Disord200621334335316211594
   PubMed Web of Science ®Google Scholar
• NavanPFindleyLJJeffsJAPearceRKBainPGDouble-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s diseaseMov Disord200318217618012539211
   PubMed Web of Science ®Google Scholar
• KorczynADBruntERLarsenJPNagyZPoeweWHRuggieriSA 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study GroupNeurology199953236437010430427
   PubMed Web of Science ®Google Scholar
• AdlerCHSethiKDHauserRARopinirole for the treatment of early Parkinson’s disease. The Ropinirole Study GroupNeurology19974923933999270567
   PubMed Web of Science ®Google Scholar
• PoeweWHRascolOQuinnNEfficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trialLancet Neurol20076651352017509486
   PubMed Web of Science ®Google Scholar
• KollerWLeesADoderMHelyMRandomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuationsMov Disord200116585886611746615
   PubMed Web of Science ®Google Scholar
• LiebermanAOlanowCWSethiKA multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study GroupNeurology1998514105710629781529
   PubMed Web of Science ®Google Scholar
• PinterMMPogarellOOertelWHEfficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre studyJ Neurol Neurosurg Psychiatry199966443644110201413
   PubMed Web of Science ®Google Scholar
• SchapiraAHBaronePHauserRAExtended-release pramipexole in advanced Parkinson disease: a randomized controlled trialNeurology201177876777421832216
   PubMed Web of Science ®Google Scholar
• MizunoYYanagisawaNKunoSRandomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s diseaseMov Disord200318101149115614534919
   PubMed Web of Science ®Google Scholar
• LiebermanARanhoskyAKortsDClinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group studyNeurology19974911621689222185
   PubMed Web of Science ®Google Scholar
• HuttonJTKollerWCAhlskogJEMulticenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s diseaseNeurology1996464106210658780092
   PubMed Web of Science ®Google Scholar
• MizunoYAbeTHasegawaKRopinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: STRONG studyMov Disord200722131860186517618525
   PubMed Web of Science ®Google Scholar
• TrenkwalderCKiesBRudzinskaMRotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER)Mov Disord2011261909921322021
   PubMed Web of Science ®Google Scholar
• PahwaRStacyMAFactorSARopinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson diseaseNeurology200768141108111517404192
   PubMed Web of Science ®Google Scholar
• BaronePLambJEllisAClarkeZSumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson’s diseaseMov Disord200722448348917115380
   PubMed Web of Science ®Google Scholar
• GuttmanMDouble-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study GroupNeurology1997494106010659339690
   PubMed Web of Science ®Google Scholar
• MöllerJCOertelWHKösterJPezzoliGProvincialiLLong-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trialMov Disord200520560261015726540
   PubMed Web of Science ®Google Scholar
• LeWittPALyonsKEPahwaRAdvanced Parkinson disease treated with rotigotine transdermal system: PREFER StudyNeurology200768161262126717438216
   PubMed Web of Science ®Google Scholar
• ImJHHaJHChoISLeeMCRopinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: a 16-week bromocriptine controlled studyJ Neurol20032501909612527999
   PubMed Web of Science ®Google Scholar
• InzelbergRNisipeanuPRabeyJMDouble-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuationsNeurology19964737857888797480
   PubMed Web of Science ®Google Scholar
• RektorováIRektorIBaresMPramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized studyEur J Neurol200310439940612823492
   PubMed Web of Science ®Google Scholar
• BruntERBrooksDJKorczynADMontastrucJLStocchiFA six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopaJ Neural Transm2002109448950211956968
   PubMed Web of Science ®Google Scholar
• SteigerMJEl-DebasTAndersonTFindleyLJMarsdenCDDouble-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuationsJ Neurol1996243168728869390
   PubMed Web of Science ®Google Scholar
• WermuthLA double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson’s diseaseEur J Neurol19985323524210210837
   PubMed Web of Science ®Google Scholar
• RascolOLeesAJSenardJMPirtosekZMontastrucJLFuellDRopinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s diseaseClin Neuropharmacol19961932342458726542
   PubMed Web of Science ®Google Scholar